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httpsWHAT THIS PAPER ADDS
A recently published genome wide association study of abdominal aortic aneurysms (AAA) identified four new
loci for AAA: SMYD2 (top single nucleotide polymorphism [SNP] rs1795061), LINC00540 (rs9316871), PCIF1/
MMP9/ZNF335 (rs3827066), and ERG (rs2836411). Based on data from a US based prospective cohort study and
a Greece based case control study, associations between rs9316871 and rs2836411 and AAA risk were replicated
in a meta-analysis of the two independent cohorts, providing further support for the importance of these loci in
the aetiology of AAA. Findings from the study contribute to improved understanding of the pathophysiology of
AAA and may aid in the management of patients with this condition.Objective: A recently published genome wide association study of abdominal aortic aneurysms (AAA), based on
pooled case control data of European ancestry, identified four new loci for AAA: SMYD2 (top single nucleotide
polymorphism [SNP] rs1795061), LINC00540 (rs9316871), PCIF1/MMP9/ZNF335 (rs3827066), and ERG
(rs2836411). Of the four, rs1795061 and rs2836411 showed significant heterogeneity across studies and the p
value for rs9316871 did not reach the genome wide significance threshold until discovery and replication data
were pooled together in that study. The objective of this study was to replicate these newly identified genetic
associations for AAA in a US based prospective cohort study, the Atherosclerosis Risk in Communities (ARIC)
Study, and a Greece based case control study.
Methods: ARIC identified 408 clinically diagnosed AAAs among 8 962 individuals of European ancestry during a
median of 22 years of follow up. The Greek case control study included 341 AAAs of European ancestry recruited
in a tertiary referral centre and 292 geographically and ethnically matched controls recruited from the same
institution. A Cox proportional hazards model was used to analyse the ARIC data and logistic regression to
analyse the Greek data.
Results: In ARIC, rs9316871 and rs3827066 were significantly associated with AAA risk (HR [p] was 0.77 [.004]
and 1.22 [.03], respectively), rs2836411 was associated at borderline significance (1.13 [.08]), whereas
rs1795061 was not associated (p ¼ .55). In the Greek case control study, rs1795061 and rs2836411 were
significantly associated with AAA (OR [p] was 1.66 [< .001] and 1.29 [.04], respectively), whereas rs9316871
was not (p ¼ .81). Genotyping of rs3827066 did not succeed. In the meta-analysis of the two studies, the
association for rs9316871and rs2836411 was statistically significant and consistent between the two studies:
p ¼ .02 and .007, respectively.
Conclusions: Associations between rs9316871and rs2836411 and AAA risk were replicated in the meta-analysis of
the two independent cohorts, providing further support for the importance of these loci in the aetiology of AAA.Keywords: Abdominal aortic aneurysm, Association, Genetic, Replication
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Replication of Newly Identified Genetic Associations for AAA 93INTRODUCTION
Significant genetic influence has been demonstrated for
abdominal aortic aneurysms (AAA), with heritability of up to
77%.1,2 Recently, Jones et al. reported a large genome wide
association study (GWAS) of AAA that pooled data from
several case control studies of populations of European
ancestry (EA).3 This study identified four new genes/loci:
SMYD2 (top single nucleotide polymorphism [SNP]
rs1795061), LINC00540 (rs9316871), PCIF1/MMP9/ZNF335
(rs3827066), and ERG (rs2836411). Of the four, rs1795061
and rs2836411 showed significant heterogeneity across
studies and the p value for rs9316871 did not reach the
genome wide significance threshold until discovery and
replication data were pooled together. It is important to
replicate these new findings in independent populations
and in prospective data. This study sought to replicate the
newly identified associations of these SNPs with AAA in two
independent studies that were not part of the study by
Jones et al.: a prospective cohort study of European
Americans with 24 years of follow up in the US, the
Atherosclerosis Risk in Communities (ARIC) Study, and a
case control study using a white Caucasian population from
Greece.MATERIALS AND METHODS
Study populations and genotyping
The ARIC Study recruited a population based cohort of
15 792 persons (73% EAs) aged 45e64 years in 1987e1989
and followed them through to 2011 for clinically diagnosed
AAAs, identified by searching hospitalisation and death re-
cords as well as Medicare data.4 Clinically diagnosed AAAs
were defined as ICD-9-CM codes of 441.3 (ruptured AAA) or
441.4 (AAA without mention of rupture), or procedure
codes of 38.44 (AAA resection and replacement) or 39.71
(AAA endovascular repair), or the following cause of death
codes: ICD-9 441.3 or 441.4 or ICD-10 code I71.3 (ruptured
AAA) or I71.4 (AAA without mention of rupture).4 Details of
AAA ascertainment and risk factor measurement in ARIC
have been described elsewhere.4 Participants who reported
AAA surgery prior to baseline (n ¼ 11 without information
on ICD codes) and uncertain AAA status during follow up
(n ¼ 30) were excluded.
ARIC extracted genomic DNA from blood and conducted
genotyping with the Affymetrix Genome-Wide Human SNP
array 6.0. To expand the number of genetic markers beyond
the genotype array for association analyses,5 ARIC con-
ducted race specific imputation of variant dosages to the
1000 Genomes Project Phase I version 3 reference panel.
Before imputation, individuals were removed for being first
degree relatives, genetic outliers, or not matching existing
genotype data. Detailed information on GWAS genotyping,
quality control, and imputation procedures has been pro-
vided elsewhere.6 Principal components (PCs) based on the
GWAS data were generated by EIGENSTRAT7 to reflect the
population structure or genetic ancestry of the ARIC par-
ticipants. Of 11 447 European Americans who were at riskof AAA at baseline in 1987e1989, 8 962 EAs had the GWAS
array genotyping and imputation data. Among them, 408
individuals were diagnosed with AAA from 1987 to 1989
through to 2011, with a median of 22 years of follow up for
the cohort.
At the end of follow up for clinically diagnosed AAAs,
ARIC conducted an ultrasound exam in 2011e2013 among
its surviving participants (n ¼ 5 911) and identified an
additional 75 asymptomatic AAAs. Ultrasound detected
AAAs were not included in this study because doing so
would require a separate analysis of these AAAs with
adjustment for the potential selection bias caused by dif-
ferential attrition of the cohort members who had the ul-
trasound, which is underpowered.
The Greek case control study prospectively recruited 418
consecutive AAA patients between July 2009 and December
2012 in a tertiary referral vascular surgery centre in northern
Greece and a group of 447 geographically matched controls
recruited within the same time interval.8 An AAA was defined
as a maximum antero-posterior diameter of the infrarenal
aorta >3.0 cm. The AAA patients, who were referred to a
vascular surgeon (on an outpatient basis) for consideration of
surgical treatment, either had an incidental diagnosis of AAA
while undergoing investigations for other conditions or were
referred via a local informal screening program. Although
rupture was not an exclusion criterion, none of the AAA
patients presented with rupture (given the logistical diffi-
culties with consent). All controls were recruited from the
same surgical unit and had cross sectional imaging of their
abdomen within four weeks of recruitment to exclude an
AAA. Cases and controls were all Caucasians born in northern
Greece. Patients with inflammatory aneurysms or connective
tissue disorders associated with aneurysm were excluded. A
full medical and surgical history was recorded at baseline,
including anthropometric assessments and a list of medica-
tions. Of the 418 AAAs and 447 controls, 341 AAAs and 292
controls had DNA samples available for genotyping for the
current study.
In the Greek case control study, DNA samples were
extracted from peripheral venous blood and stored at 4 C
until analysis. The candidate SNPs were identified using
LightSNip (TIB MOLBIOL GmbH, Berlin, Germany) on the
Roche LightCycler 480 system (Roche Diagnostics Corp,
Indianapolis, IN, USA) based on real time polymerase chain
reaction and melting curve analysis. The LightCycler 480
instrument was programmed according to the instructions
for use for each LightSNip. DNA samples of both AAAs and
controls were included in each plate. Clinical data were not
available during genotyping. Genotyping for rs3827066
failed because of insufficient quality and quantity of DNA
samples. Sixty-four duplicate samples were included in the
genotyping, yielding an overall concordance rate of 98.6%
between the duplicates. Three AAAs were excluded from all
analyses because of questionable allele calls or missing data
for more than one of the SNPs. After further exclusion of
missingness for each individual SNP, the final sample size
was 333 AAAs and 292 controls for rs1795061, 336 and 292
for rs9316871, and 323 and 291 for rs2836411.
94 Weihong Tang et al.In both studies, all participants provided informed
consent, and the institutional review board or ethics
committee at each institute approved the study. None of
the data on the associations between AAA and the four
genetic markers in ARIC or the Greek study have been
published previously.Statistical analysis
In ARIC, Cox proportional hazards regression was used to
test the association of SNP allele dosages with AAA, with
time to event calculated from baseline to the time of first
AAA event, date of death, loss to follow up, or through
December 31, 2011, whichever came first. HR and 95% CI
were computed with adjustment for age, sex, field centre
(i.e., study site), and the first five PCs for population strat-
ification to reduce potential confounding by these
characteristics.
In the Greek case control study, logistic regression was
performed to calculate OR and 95% CI to assess the asso-
ciation between the allele dosage of each SNP and AAA
status, with adjustment for age and sex.
In both studies, the at risk allele was chosen to be
consistent with the report by Jones et al.3Meta-analysis
To reduce the influence of variation of individual studies
and increase statistical precision, a sample size weighted
meta-analysis was used to pool p values and direction of
genetic effects from the two studies for rs1795061,
rs9316871, and rs2836411. The p value based approach was
chosen because different study designs were used which
yielded different effect estimates (HR vs. OR) in the two
studies. The number of AAAs in each study was used as theTable 1. Baseline characteristics of patients with and without a
Communities (ARIC) cohort study (1987e2011) and Greek case coh
Baseline characteristics ARIC cohort study
AAA (n [ 408) Non-AAA (n [ 8554
Age, years 57  5 55  6
Male 295 (72) 3875 (45)
Body mass index kg/m2 27  4 27  5
Smoking status
Current smoker 206 (50) 1984 (23)
Former smoker 151 (37) 3037 (35)
Never smoker 51 (13) 3533 (41)
Pack-years smokingc 35  24 16  21
Hypertension 149 (37) 2250 (26)
Peripheral arterial disease 20 (5) 163 (2)
Diabetes 24 (6) 744 (9)
Hypercholesterolaemia 147 (36) 2224 (26)
Data are provided as n (%) or mean  standard deviation (SD).
AAA ¼ abdominal aortic aneurysm; ARIC ¼ Atherosclerosis Risk in Comm
a n was 333 AAAs for rs1795061, 336 AAAs for rs9316871, and 323 AAA
b n was 292 controls for both rs1795061 and rs9316871, and 291 contro
c Including non-smokers.weight. An I2 was estimated in a heterogeneity test to
assess the difference of test statistics and the direction of
association between the two studies. Furthermore, the data
from the two studies were pooled with those from Jones
et al. to evaluate whether adding the ARIC and Greek data
strengthened the overall GWAS associations of Jones et al.
The meta-analyses were conducted using the METAL
package.9Power analysis
The power was estimated to replicate the associations for
the three SNPs reported by Jones et al. in the combined
ARIC and Greek samples. At an a of 0.05, there was
acceptable power to replicate the reported associations in
the pooled ARIC and Greek samples: rs1795061 (MAF 0.34,
OR 1.13, power 61%), rs9316871 (0.20, 0.86, 62%), and
rs2836411 (0.37, 1.13, 60%).RESULTS
Table 1 presents the baseline characteristics of the two
study populations.
In ARIC, rs2836411 and rs9316871 were genotyped while
rs1795061 and rs3827066 were imputed. Imputation qual-
ity, reflected by the ratio of observed to expected variance
of the dosage statistic, was excellent for these two SNPs
(0.98 and 0.99, respectively). In the whole study population,
a test of genotype frequencies against HardyeWeinberg
equilibrium was marginally significant for rs2836411
(p ¼ .05) and not significant for the other three SNPs. Minor
allele frequencies (MAF) for the four SNPs agreed with
those in Jones et al.3 After adjustment for age, sex, field
centre, and the first five PCs, rs9316871 and rs3827066
were significantly associated with AAA (HR [95% CI] 0.77bdominal aortic aneurysm (AAA) in Atherosclerosis Risk in
ort study
Greek case control study
) p AAA (n [ 338a) Controls (n [ 292b) p
<.001 69  8 73  5 .001
<.001 310 (92) 219 (75) .006
.10 28  3 27  3 .73
<.001 .43
66 (20) 63 (22)
192 (57) 149 (51)
80 (24) 80 (27)
<.001 NA NA NA
<.001 260 (77) 226 (77) .87
<.001 71 (21) 51 (17) .27
.05 75 (22) 68 (23) .78
<.001 196 (58) 155 (53) .20
unities; NA ¼ not assessed or available.
s for rs2836411.
ls for rs2836411.
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copy increase in the effect allele dose), and rs2836411 was
close to the threshold for significance (HR [95% CI] 1.13
[0.99e1.31], p ¼ .08) (Model 1 in Table 2). Notably, the
association for rs9316871 suggests a protective effect
associated with the minor allele G. The direction of asso-
ciation for the three SNPs was consistent with that of Jones
et al.3 rs1795061 was not associated with AAA in ARIC
(p ¼ .55) (Model 1 in Table 2).
In the Greek case control study, genotype frequencies for
rs1795061, rs9316871, and rs2836411 were in accordance
with HardyeWeinberg equilibrium (p > .05) in the controls.
MAF for rs1795061 was lower than that in ARIC and Jones
et al., whereas MAF for the other two SNPs was similar to
that of ARIC and Jones et al. rs1795061 and rs2836411 were
significantly associated with the risk of AAA (OR [95% CI] 1.66
[1.27e2.17] and 1.29 [1.01e1.65], respectively) (Model 1 in
Table 2), rs9316871 was not associated with AAA (p ¼ .81).
Associations of rs1795061, rs9316871, and rs2836411
with AAA were statistically significant in the meta-analysis
of the two studies (Model 1 in Table 2). Heterogeneity
(I2 > 0) was observed for rs1795061 and rs9316871, with
that for rs1795061 being statistically significant (p < .05).
The direction of association for rs1795061 was not consis-
tent between the two studies. Pooling the data of the two
studies with those from Jones et al. in a second meta-
analysis strengthened the statistical significance of the
GWAS associations for the four SNPs (Model 1 in Table 2).Table 2. Association between novel abdominal aortic aneurysm
Atherosclerosis Risk in Communities (ARIC) cohort study (1987e2




HR (95% CI)a p MAF
Model 1
rs1795061 SMYD2 Te C .31 0.96 (0.82e1.12) .55 .21




Te C .16 1.22 (1.02e1.46) .03 NA
rs2836411 ERG Te C .34 1.13 (0.99e1.31) .08 .33
Model 2
rs1795061 SMYD2 Te C .31 0.95 (0.81e1.11) .52 .21




Te C .16 1.20 (1.01e1.43) .04 NA
rs2836411 ERG Te C .34 1.12 (0.97e1.30) .11 .33
AAA ¼ abdominal aortic aneurysm; A1 ¼ effective allele, A2 ¼ alternative
allele frequency; NA ¼ not available or applicable; SNP ¼ single nucleoti
a HR were modelled per 1 unit increment in the effect allele dose in Cox re
field centre, and the first five principal components for population stratific
and total cholesterol).
b Meta-analysis 1: Atherosclerosis Risk in Communities (ARIC) and the G
c Meta-analysis 2: ARIC, the Greek case control study (not for rs3827066
d OR were modelled per one unit increment in the effect allele dose in logis
and sex) or Model 2 (Model 1 further adjusted for smoking status and bin
e Minor allele.
f p < .05, other I2 without this label had p > .05.In a secondary analysis, further adjustments were made
for two important risk factors for AAA, smoking (pack years
of smoking in ARIC and smoking status in the Greek study)
and cholesterol (total cholesterol in ARIC and binary
hypercholesterolaemia in the Greek study). The additional
adjustments did not result in appreciable changes in either
individual study or the meta-analyses (Model 2 in Table 2).
As a note, 12 AAAs and 99 non-AAAs in ARIC were excluded
from this analysis because of missing information on the
smoking variable.DISCUSSION
This study replicated the previously reported new associations
of AAA risk with rs9316871 and rs3827066 in the US based
prospective study, and with rs1795061 and rs2836411 in the
Greek case control study. The direction of association with
rs9316871 and rs2836411 was consistent between the two
studies and the associations were significant in the meta-
analysis combining the two studies. The ARIC data showed
the association of rs9316871, rs3827066, and rs2836411 with
longitudinal AAA risk based on 24 years of follow up. To the
best of the present authors’ knowledge, there are few data in
the literature reporting longitudinal AAA risk associated with
genetic variants in a community based study.While the effect
size for the replicated variants was modest, their public health
implication is not trivial because their at risk alleles are com-
mon in the general population.(AAA) single nucleotide polymorphism (SNPs) and AAA in
011) and Greek case control study
case control study Meta-analysis 1b Meta-analysis 2c
OR (95% CI)d p Dir p I2 Dir p I2
1.66 (1.27e2.17) 1.96  104 eþ .04 90f eþþ 1.1  1011 80f
0.97 (0.75e1.25) .81 e .02 68 e 3.8  1011 42
NA NA NA NA NA þþ 2.2  1018 0
1.29 (1.01e1.65) .04 þþ .007 0 þþþ 2.6  1010 0
1.71 (1.30e2.23) 9.6  105 eþ .03 91f eþþ 8.8  1012 82f
0.97 (0.75e1.26) .83 e .01 74 e 3.0  1011 54
NA NA NA NA NA þþ 2.8  1018 0
1.27 (0.99e1.62) .06 þþ .01 0.1 þþþ 3.9  1010 0
allele; Dir ¼ direction; I2 ¼ heterogeneity test statistics; MAF ¼ minor
de polymorphism; HR ¼ hazard ratio; OR ¼ odds ratio.
gression, with covariable adjustment in Model 1 (adjusted for age, sex,
ation) or Model 2 (Model 1 further adjusted for pack years of smoking
reek case control study (not for rs3827066).
), and Jones et al.3.
tic regression, with covariable adjustment in Model 1 (adjusted for age
ary hypercholesterolemia).
96 Weihong Tang et al.By extensive look up in expression quantitative trait locus
and RNA sequencing data, Jones et al. identified functional
relevance for three of the variants: rs3827066 with PLTP
expression, rs2836411 with ERG expression, and rs9316871
with FGF9 expression.3 They also searched for these puta-
tive AAA risk variants in published GWAS data of other
cardiometabolic phenotypes but did not find associations of
the new variants with coronary artery disease (CAD), hy-
pertension, lipid traits, or diabetes. However, a newly
published GWAS for CAD identified rs3827066 in PCIF1-
ZNF335-MMP9 as a new locus for CAD (OR 1.04).10 This
new GWAS finding further highlights the overlap between
genetic risk factors for AAA and other forms of cardiovas-
cular disease.
In Jones et al., the p for rs9316871 in LINC00540 reached
the genome wide significance threshold only when the
discovery and replication data were pooled together.
Therefore, the replication of this locus in ARIC provides
further corroboration that it is related to the risk of AAA.
The association at this locus showed modest heterogeneity
between ARIC and the Greek study, with consistent direc-
tion. Unlike the analysis in ARIC, the Greek study did not
control for possible population stratification using ancestry
informative markers or principal components. However, the
threat of confounding by population stratification is prob-
ably small, although cannot be completely ruled out,
because both cases and controls were Caucasians who were
recruited from and born in a small area of northern Greece.
The association between rs1795061 and AAA risk was
replicated in the Greek study but not in ARIC (p ¼ .55). In
fact, the direction of association in ARIC was opposite to
that in the Greek study and the GWAS by Jones et al.
Imputation error was an unlikely explanation because
rs1795061 was imputed with high confidence in ARIC
(imputation quality score 0.98). The MAF was similar in ARIC
and Jones et al. (0.31 vs. 0.34) but lower in the Greek study
(0.21 among the controls). The association of this SNP with
AAA also showed high heterogeneity across studies in Jones
et al. As rs1795061 is located at an intergenic region near
SMYD2 and GWAS is an indirect mapping strategy that re-
lies on variants that are in linkage disequilibrium (LD) with
the true causal variants to capture the genetic associa-
tions,11,12 it is possible that the rs1795061-AAA association
reflects the effect of an underlying, causal variant that was
not directly measured by the GWAS arrays. If so, the extent
of LD between rs1795061 and the underlying causal variant
may differ across populations. Another interpretation is that
different genetic backgrounds and environmental exposures
may have modified the effect of this locus in different
populations.
In summary, based on the data from two independent
populations of European ancestry, the present study
consistently replicated newly reported associations for AAA
at LINC00540 and ERG, further supporting the importance
of these loci in the aetiology of AAA. Improved under-
standing of AAA aetiology might benefit the management of
AAA and suggest new primary prevention or therapeutic
strategies. Future studies in diverse populations are neededto further validate these genetic loci as risk factors for AAA
as well as to identify the underlying causal variants and
mechanisms for validated associations. Furthermore, with
the increasing number of genetic loci and variants that
might be identified for AAA in future studies, it may be
worth evaluating the efficiency of genetic testing in rela-
tives of AAA patients for the identification of individuals at
increased risk of developing AAA. Notably, the potential
value of using genomic information in cardiovascular risk
prediction has recently been demonstrated in the field, for
example, on CAD.13 Future studies with comprehensive
assessment of genomic variants in large populations will be
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